Pharmaceutical Drug Development Process Explained by Medical Expert

Added:

Systemic Flaws and Underreporting of Persistent Side Effects in Clinical Trials

Critics and independent researchers argue that the standard pharmaceutical R&D process often fails to adequately identify and address long-term or persistent side effects, such as sexual dysfunction. Because clinical trials are typically short-term, funded by the pharmaceutical industry, and rely on standardized questionnaires that may not capture complex quality-of-life issues, long-term adverse events can be overlooked or minimized. For instance, conditions like Post-SSRI Sexual Dysfunction (PSSD) and Post-Finasteride Syndrome (PFS) frequently emerge or persist long after drug discontinuation, yet they are rarely captured during initial R&D phases. Critics advocate for independent trial designs, longer follow-up periods, and a greater emphasis on patient-reported outcomes to ensure that the true risk-benefit profile of a drug is transparently communicated to the public, rather than relying solely on industry-sponsored expert narratives.

Basic concepts of pharmacology, including pharmacokinetics (how the body processes drugs) and pharmacodynamics (how drugs affect the body).
An overview of the clinical trial process, specifically the distinct objectives of Phase I, II, and III human trials.
Fundamental human anatomy and physiology, particularly how the nervous and endocrine systems regulate systemic bodily functions.
The role of regulatory bodies, such as the FDA, in establishing guidelines for drug safety, efficacy, and labeling.
Advanced principles of Pharmacovigilance, focusing on post-marketing surveillance (Phase IV) and signal detection for adverse drug reactions.
The concept of drug repurposing (repositioning), where side effects discovered during trials lead to new therapeutic indications.
Pharmacogenomics, exploring how genetic variations among individuals influence drug metabolism and the occurrence of side effects.
Bioethics in clinical research, including patient safety, informed consent, and the ethics of reporting adverse trial outcomes.
72.2K views1.8Klikes1:03:50@YMHStudiosOriginal Release: 2023-09-29

Pharmaceutical research follows a strict timeline where companies have only 10 years from identifying a molecule to bring it to market and profit, with an average of 5 years and over $1 billion required to develop a new drug. This economic pressure drives pharmaceutical companies to create 'me-too' drugs (slight modifications of existing drugs) to maximize profits during the patent period, as they only have 5 years to recoup their investment before the drug becomes generic and loses patent protection.